Originally published May 2021. Updated August 2026.
FDA and EMA require a documented nitrosamine risk assessment before any lab testing begins. Manufacturers review synthesis routes, raw materials, and storage conditions for points where secondary or tertiary amines could react with nitrosating agents.
The resulting risk profile falls into two categories: small-molecule nitrosamines, common across unrelated drug products, and nitrosamine drug substance-related impurities (NDSRIs), unique to the API itself. Nitrosamines testing confirms what that risk assessment flags as possible.
This post covers how the FDA and EMA frameworks assess risk, where the requirements diverge, and what analytical work follows a positive risk finding.
Key Takeaways
- Risk assessment comes before testing: A documented review of manufacturing and raw materials determines whether lab analysis is required at all.
- Small-molecule nitrosamines and NDSRIs follow different limit-setting logic: FDA’s 2023 guidance introduced a structure-based method specific to NDSRIs.
- EMA’s review runs on a three-step cycle: Risk evaluation, confirmatory testing, and marketing authorization updates.
- Acceptable intake limits shift as new data arrives: Both agencies have revised limits for individual compounds as new toxicology data becomes available.
- Method sensitivity determines whether a lab can support submission-ready data: GC-MS/MS and LC-MS/MS methods must be validated to the specific limit and matrix involved.
At a Glance: Nitrosamine Risk Assessment Requirements
Question | Short Answer |
Which compounds require evaluation? | Small-molecule nitrosamines (NDMA, NDEA, and related compounds) and NDSRIs specific to the API |
Who sets the acceptable intake limits? | FDA, using a carcinogenic potency categorization approach, and EMA, through its Article 5(3) opinion |
What triggers lab testing? | A risk evaluation that identifies a plausible pathway for nitrosamine formation or contamination |
What confirms the finding? | Validated GC-MS/MS or LC-MS/MS testing at the relevant acceptable intake limit |
What happens after a confirmed result? | Reporting to the relevant agency and updating specifications or marketing authorization filings |
Why Nitrosamines Draw This Level of Scrutiny
How Nitrosamines Form in Drug Manufacturing
Nitrosamines belong to a class of compounds that react with DNA, and regulatory agencies classify several of them as probable human carcinogens. The 2018 discovery of NDMA in valsartan and related sartan products triggered a global review of manufacturing processes, since the conditions that generate nitrosamines (secondary or tertiary amines reacting with nitrosating agents under acidic conditions) span many synthesis routes and drug classes. Recycled solvents and reagents introduce a second contamination pathway, since residual nitrites can persist through recovery processes independent of the primary synthesis route.
How FDA and EMA Responded
FDA and EMA responded with parallel but distinct frameworks. Both require a nitrosamine risk assessment before testing, both set acceptable intake (AI) limits from lifetime cancer risk modeling, and both expect ongoing monitoring alongside the initial assessment. They diverge in how they classify nitrosamine subtypes and calculate limits for compounds lacking compound-specific toxicology data.
How FDA Classifies Nitrosamine Risk
FDA’s Control of Nitrosamine Impurities in Human Drugs guidance, revised most recently in September 2024, separates nitrosamine impurities into two categories.
Small-Molecule Nitrosamines
Compounds such as NDMA, N-nitrosodiethylamine (NDEA), and related solvent- or reagent-derived nitrosamines can appear across many unrelated APIs. FDA’s original 2021 guidance set a default reporting threshold of 26.5 ng/day for most of these compounds, a limit that lines up closely with USP <1469> nitrosamine impurity testing requirements, with limits for individual compounds adjusted as new mutagenicity data becomes available.
Nitrosamine Drug Substance-Related Impurities
NDSRIs form from the API’s own structure and are typically unique to each drug substance. Because most NDSRIs lack compound-specific carcinogenicity data, FDA’s August 2023 guidance introduced the Carcinogenic Potency Categorization Approach (CPCA), a rule-based method that assigns a predicted potency category and corresponding AI limit from the molecule’s structural features. The guidance provided recommended AI limits for 247 NDSRIs using this method, a substantial expansion from the six compounds with established limits under the earlier 2021 guidance. FDA prioritizes compound-specific or read-across data where available, reserving CPCA for compounds lacking either.
How EMA’s Review Framework Works
EMA’s guidance stems from a CHMP Article 5(3) opinion on nitrosamine impurities in human medicines, structured around three defined steps.
Step One: The Nitrosamine Risk Assessment
Marketing authorization holders (MAHs) review synthesis routes, raw materials, and storage conditions for each product to identify any plausible risk of nitrosamine formation or cross-contamination, mirroring FDA’s initial risk assessment.
Step Two: Confirmatory Testing
Where a risk is identified, MAHs commission analytical testing to confirm or rule out nitrosamines at levels of regulatory concern. EMA’s accompanying Q&A guidance specifies acceptable testing conditions and flags known limitations, including reduced Ames assay sensitivity for certain nitrosamine structures.
Step Three: Updating Marketing Authorizations
A confirmed finding requires MAHs to update product specifications, labeling, or the marketing authorization itself, and to implement corrective and preventive measures. EMA generally expects this work completed within three years of when the relevant AI limit is established, with earlier notification required if a manufacturer anticipates missing that window.
Building a Defensible Nitrosamine Risk Assessment
A nitrosamine risk assessment holds up under regulatory review when it addresses each of the following systematically:
- Synthesis route review — every reaction step where a secondary or tertiary amine could contact a nitrosating agent, including intermediates
- Raw material sourcing — supplier history, especially for recycled or reclaimed solvents and catalysts
- Formulation and packaging interactions — excipients or container materials that introduce nitrite sources
- Storage and shelf-life conditions — temperature and humidity that could accelerate formation over time
- Prior contamination history — findings from related products on shared equipment or suppliers
Manufacturers typically retain this document rather than submitting it proactively, though both agencies expect it available on request.
Analytical Methods for Nitrosamine Testing
Method selection depends on the nitrosamine in question and the sample matrix.
Choosing Between GC-MS/MS and LC-MS/MS Nitrosamine Testing
- GC-MS/MS serves as the standard approach for most small-molecule nitrosamines, typically using a triple quadrupole mass detector for the sensitivity these low acceptable intake limits require
- LC-MS/MS becomes the preferred method for compounds prone to thermal degradation during GC analysis, most notably NDMA in ranitidine, where GC injection port temperatures generate a false positive through drug substance breakdown
- Method validation against ICH Q2(R1) principles confirms that a method performs reliably at the specific AI limit and matrix involved, since a published FDA or EMA reference method still requires lab-specific validation before supporting a submission
Analytical method development and validation for nitrosamine testing typically adapts a published reference method to the product matrix, then validates it.
What Changes as Guidance Evolves
Nitrosamine guidance has continued to shift since the initial 2020 FDA framework, and a testing program built against outdated limits can miss compounds now in scope.
FDA Updates Since 2021
The August 2023 NDSRI guidance introduced CPCA-based limits for compounds that previously had none. FDA’s September 2024 revision then consolidated small-molecule and NDSRI recommendations into a single document.
EMA Updates Since 2021
EMA updated its Q&A appendices in 2024 to re-evaluate AI values for several solvent-related nitrosamines, using the same CPCA methodology FDA introduced.
Manufacturers working from a 2021-era risk assessment benefit from re-checking current compounds and limits against these updates. A closer look at GC-MS and LC-MS analysis of nitrosamines covers instrumentation and method selection in more depth.
Nitrosamine Testing: Common Questions
What is the difference between a small-molecule nitrosamine and an NDSRI?
Small-molecule nitrosamines can form independently of the API and appear across unrelated drug products, while NDSRIs form from the API’s own structure and are typically unique to that specific drug substance.
Does every drug product require nitrosamine testing?
Testing follows a positive risk assessment finding; products where the synthesis route, raw materials, and storage conditions show no plausible nitrosamine formation pathway typically skip confirmatory lab work.
Why does ranitidine require LC-MS instead of GC-MS?
Ranitidine’s molecular structure degrades under GC injection port temperatures in a way that generates NDMA as an artifact of the test itself, so LC-MS avoids the thermal exposure that causes this false result.
How often should a nitrosamine risk assessment be updated?
A risk assessment should be revisited whenever FDA or EMA guidance changes the compounds or limits in scope, and whenever a manufacturing change introduces a new raw material, supplier, or process step.
What documentation should a lab provide alongside nitrosamine test results?
Method validation data specific to the compound and matrix tested, along with clear traceability to the applicable FDA or EMA acceptable intake limit, supports the results in a regulatory submission.
Get Nitrosamine Testing Support From BA Sciences
BA Sciences develops and validates nitrosamine testing methods for small-molecule nitrosamines and NDSRIs, using GC-MS/MS and LC-MS/MS platforms suited to the compound and matrix involved. Our team supports manufacturers working through USP <1469> requirements, FDA and EMA risk assessment documentation, and confirmatory testing timelines. Request a quote to discuss your product’s nitrosamine testing needs.
Read More:
You Should Own Your Analytical Methods: What That Means and Why It Matters
Extractables vs. Leachables: When Each Study Is Required and How to Structure Your Risk Assessment
What Is Protein Characterization? Techniques and Applications